News
AMRN
0.9751
-0.50%
-0.0049
Weekly Report: what happened at AMRN last week (0429-0503)?
Weekly Report · 2d ago
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
NASDAQ · 5d ago
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
NASDAQ · 5d ago
Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
NASDAQ · 05/01 16:35
Amarin’s Sell Rating Affirmed Amid US Market Challenges and Uncertain European Growth
TipRanks · 05/01 14:25
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
NASDAQ · 05/01 13:14
Amarin Corporation plc 10-Q Quarterly Report
Press release · 05/01 13:06
AMARIN CORP - ON-TRACK TO DELIVER $40 MLN OF ANNUAL SAVINGS BASED ON REDUCTION IN FORCE ANNOUNCED IN JULY 2023
Reuters · 05/01 11:00
AMARIN CORP - SHARE REPURCHASE PROGRAM OF UP TO $50 MLN APPROVED BY SHAREHOLDERS
Reuters · 05/01 11:00
Notable earnings before Wednesday's open
Major earnings expected before the bell on Wednesday include: Ares Capital, CVS Health, Barrick Gold, Mastercard and Pfizer. Other notable earnings slated for release before Wednesday's open include: YUM, Ares Capital and Ares Capital. For Seeking Alpha's earnings season calendar, click here.
Seeking Alpha · 04/30 14:46
Weekly Report: what happened at AMRN last week (0422-0426)?
Weekly Report · 04/29 09:58
12 Health Care Stocks Moving In Wednesday's After-Market Session
Acrivon Therapeutics stock rose 12.3% to $10.67 during Wednesday's after-market session. The company's, Q1 earnings came out today. Amarin Corp stock moved upwards by 8.12% and Universe Pharmaceuticals stock rose 7.47% in the same session.
Benzinga · 04/24 20:31
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
Petition filed with the FDA to address significant off-label prescribing of fenofibrates. The filing comes as heart disease continues to be the leading cause of death in the United States. Amarin Corporation plc has no clinical benefit when used in combination with statins to reduce cardiovascular disease risk.
Barchart · 04/24 13:00
Amarin Shareholders Show Strong Support at Annual Meeting
TipRanks · 04/22 17:12
Weekly Report: what happened at AMRN last week (0415-0419)?
Weekly Report · 04/22 09:55
Amarin Corporation: Small Signs Of Recovery May Not Be Enough
Home Healthcare Amarin Corporation: Small Signs Of Recovery May Not be Enough. Amarin is going through a turbulent period with a contraction in revenue and margins. The EU and China markets seem too small to make significant changes. The US market is suffering from margin erosion. The number of hedge funds that are investing in Amarin plc is reducing.
Seeking Alpha · 04/16 17:51
Weekly Report: what happened at AMRN last week (0408-0412)?
Weekly Report · 04/15 09:51
Weekly Report: what happened at AMRN last week (0401-0405)?
Weekly Report · 04/08 09:53
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
Amarin Corporation plc highlighted three data presentations at ACC.24 showcasing the mechanistic activity of Eicosapentaenoic acid (EPA) Three data presentations highlight potential effects of EPA on endothelial cell dysfunction and on oxidation of samples enriched with Lp(a)
Barchart · 04/08 07:00
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
Barchart · 04/06 14:30
More
Webull provides a variety of real-time AMRN stock news. You can receive the latest news about Amarin through multiple platforms. This information may help you make smarter investment decisions.
About AMRN
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.